Novartis buys Oriel Therapeutics

Swiss drugmaker Novartis has bought privately held US company Oriel Therapeutics to boost its generics portfolio in the multibillion-dollar market for respiratory drugs. The move suggests the Swiss drugmaker may see a simpler route to market with Oriel’s electronic inhaler device than with another device from Britain's Vectura Group.